Royal Bank of Canada
PBYI icon

Royal Bank of Canada’s Puma Biotechnology PBYI Stock Holding History

Royal Bank of Canada’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-400
Closed -$5K – 7002
2019
Q2 		$5K Buy
+400
New +$9.21K ﹤0.01% 6317

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royal Bank of Canada's PBYI Position: Q2 2026 in Review

Royal Bank of Canada reduced its Puma Biotechnology (PBYI) stake by 45% in Q2 2026, selling an estimated $14.2K and leaving 2,386 shares worth $20K. The position accounts for ﹤0.01% of the portfolio, ranked #6342.

Royal Bank of Canada first reported a position in PBYI in Q2 2013 and has held it in 50 quarters since. The position peaked at $3.3M in Q4 2013. 160 funds tracked by Wall St. Rank hold PBYI as of Q2 2026.

  • Royal Bank of Canada held 2,386 shares of Puma Biotechnology worth $20K as of Q2 2026.
  • Royal Bank of Canada sold 1,934 Puma Biotechnology shares in Q2 2026, an estimated $14.2K.
  • Puma Biotechnology made up ﹤0.01% of Royal Bank of Canada's portfolio in Q2 2026, its #6342 holding.
  • Royal Bank of Canada first reported a position in Puma Biotechnology in Q2 2013 and has held it in 50 quarters since.
  • Royal Bank of Canada's Puma Biotechnology position peaked at $3.3M in Q4 2013.
  • 160 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2026.

Based on Royal Bank of Canada's 13F filing for Q2 2026, filed 14 Aug 2026.